A newly-developed contraceptive targeted toward cisgender men has a 99 percent success rate in preventing pregnancy in mice, according to an article published by The New York Times on March 25, 2022. A report published by HealthDay found that past studies of cis male contraceptives have focused on targeting testosterone levels, whereas the current contraceptive in development works to reduce the functioning of a protein called retinoic acid receptor alpha, which affects sperm formation, embryonic development and cell growth. Researchers explained that this change in direction was due to the adverse side effects that often occur as a result of hormonal-based medication, such as weight gain, depression and high levels of cholesterol. Researchers also noted that the mice regained the ability to reproduce four to six weeks after halting regular pill consumption.